Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — H.C. Wainwright 23rd Annual Global Investment Conference (September 2021)
18 slides from Aethlon Medical's conference presentation, September 2021
Slide 1: H.C. Wainwright 23rd Annual Global Investment Conference Presentation
H.C. Wainwright 23rd Annual Global Investment Conference Presentation September 2021 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619-941-0360 Nasdaq: AEMD www.AethlonMedical.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll patients in the Early Feasibility Studies; the ability to successfully compl
Slide 3: The Aethlon Hemopurifier®
The Aethlon Hemopurifier® FDA designated “Breakthrough Device” • Safely administered in > 150 patient treatments • Proprietary mechanism of action • Clears life-threatening glycosylated viruses • Designed to clear cancer promoting exosomes 3
Slide 4: Aethlon Medical, Inc.
Aethlon Medical, Inc. • Headquartered in San Diego, CA (NASDQ: AEMD) • Focused on combating infectious disease and cancer with immunotherapeutic technologies • Augment the body's natural immune defenses by eliminating life-threatening disease targets that are often shielded from the immune system an
Slide 5: Aethlon's senior management team has extensive experience with both medical devices and therapeutics
Aethlon’s senior management team has extensive experience with both medical devices and therapeutics Companies Charles J. Fisher, Jr., MD, FACP, FCCP, FCCM, Chief Executive Officer • Academic & Industry thought leader in sepsis & inflammation • Head of critical care—Cleveland Clinic • 35 years indus
Slide 6: The Hemopurifier®'s unique mechanism of action captures virus and exosomes from a patient's blood
The Hemopurifier®’s unique mechanism of action captures virus and exosomes from a patient’s blood via extracorporeal circuit A B Captures enveloped viral pathogens and exosomes in circulating blood • Hollow-fiber plasma separator filled with proprietary “affinity resin” [figures B, C] C • Size restr
Slide 7: Hemopurifier® Pipeline
Hemopurifier® Pipeline Early Feasibility Indication Pre-Clinical Pivotal Study Study HNSCC IDE Protocol – Tx Before Keytruda Oncology Other Solid TBD Tumors Covid-19 Emergency Use & IDE Protocol Viral Infection Ebola Emergency Use HCV Safety Testing HIV Emergency Use & IDE Protocol Other TBD 7
Slide 8: Hemopurifier® Treatment for Oncology
Hemopurifier® Treatment for Oncology • Clearance of cancer promoting exosomes • Potentially synergistic with immunotherapy, targeted agents, chemotherapy • Multiple potential clinical targets • Head and neck, breast, gastrointestinal, melanoma, other solid tumors • Well characterized markets, develo
Slide 9: Rationale for exosome removal in cancer
Rationale for exosome removal in cancer • Key mediators in cell communication and potent drivers in healing and repair • Exosomes shed from both normal and malignant cells • Tumor derived exosomes promote metastasis, treatment resistance, immune suppression • No other known treatment in development
Slide 10: Tumor-derived exosomes are released by tumor cells
Tumor-derived exosomes are released by tumor cells Cell membrane Tumor-derived exosomes Cytoplasm 10
Slide 11: National Cancer Institute studies underway or completed
National Cancer Institute studies underway or completed • Phase I contract from NCI — Completed • “Device Strategy for Differential Isolation of Oncosomes and Non-Malignant Exosomes” • NCI SBIR Grant — Completed • “The Hemopurifier® Device for Targeted Removal of Breast Cancer Exosomes from the Bloo
Slide 12: Early Feasibility Study in Head and Neck Cancer
Early Feasibility Study in Head and Neck Cancer • NCT #04453046 • University of Pittsburgh Hillman Cancer Center • 10-12 subjects with advanced or metastatic HNSSC • Combination with pembrolizumab (Keytruda®) • Keytruda approved June 2019 in front line setting • 4-hour Hemopurifier treatment immedia
Slide 13: Rationale for Hemopurifier® treatment of viral infections
Rationale for Hemopurifier® treatment of viral infections • Demonstrated clearance of multiple different viruses in vitro • HIV, dengue, West Nile, influenza, Ebola, herpes, MERS • Safety and viral clearance in four human clinical trials in HCV • Over 120 Hemopurifier applications in humans with HCV
Slide 14: Rationale for Hemopurifier® treatment of SARS-CoV-2/COVID-19
Rationale for Hemopurifier® treatment of SARS-CoV-2/COVID-19 • Circulating virus correlates with cytokine levels and poor outcome • Hemopurifier has been shown to clear MERS, another coronavirus • Clears SARS-CoV-2/COVID-19 glycoproteins based on in vitro experiments • IDE supplement for COVID-19 ap
Slide 15: Strong Cash Position
Strong Cash Position • June 30, 2021 Company’s cash balance was approximately $25.1 million • No debt • NASDAQ: AEMD ~15.4 million shares outstanding 15
Slide 16: Summary
Summary ▪ Unique Hemopurifier® blood purification device ▪ Two FDA Breakthrough Therapy Designations ▪ Multiple therapeutic targets in cancer and viral disease ▪ Demonstrated virus and exosome clearance in patients ▪ Management team with well over 100 years healthcare experience 16
Slide 17: Upcoming News
Aethlon Hemopurifier® Upcoming News 2021-2022 ▪ IDE supplement approved for SARS-CoV-2/COVID-19 ✔ ▪ Emergency treatment of SARS-CoV-2/COVID-19 patients ✔ ▪ EFS initiated for head and neck cancer and first patient treated ✔ ▪ Expected News: ▪ Updates on SARS-CoV-2 trial ▪ Early clinical data from EFS
Slide 18: 11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 Nasdaq: AEMD
11555 Sorrento Valley Road, Suite 203 San Diego, California 92121 619-941-0360 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully
Aethlon Medical — H.C. Wainwright 23rd Annual Global Investment Conference (September 2021) on 6ix